(Q24234963)

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Unresectable squamous cell carcinoma of the lung and its management by combined bleomycin and radiotherapy.A clinical study of the enhanced results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

A prospective and randomized study of radiotherapy, sequential chemotherapy radiotherapy and concomitant chemotherapy-radiotherapy in unresectable non small cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Chemotherapy for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Concurrent chemoradiotherapy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

Split-course irradiation compared to split-course irradiation plus hydroxyurea in inoperable bronchogenic carcinoma--a randomized study of 53 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

A randomized prospective study of radiation versus radiation plus ACNU in inoperable non-small cell carcinoma of the lung. Japan Radiation-ACNU Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Effect of concomitant use of pentoxifylline and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer: a randomized prospective clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB3

7 January 2021

10.1002/14651858.CD002140.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

20556756

1 reference

Consolidated OpenCitations Corpus – April 2017